株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

血友病遺伝子治療の世界市場 - 市場規模、シェア、動向、予測 2026年

Hemophilia Gene Therapy Market - Size, Share, Trends, and Forecast to 2026

発行 Coherent Market Insights 商品コード 798075
出版日 ページ情報 英文 110 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.43円で換算しております。
Back to Top
血友病遺伝子治療の世界市場 - 市場規模、シェア、動向、予測 2026年 Hemophilia Gene Therapy Market - Size, Share, Trends, and Forecast to 2026
出版日: 2019年02月07日 ページ情報: 英文 110 Pages
概要

血友病の有病数の増加、コストの高さ、凝固因子VIIIおよびIXを利用する現行の血友病治療へのアクセス性、遺伝子治療商品の研究開発を行う企業の増加などによって、血友病遺伝子治療市場の成長が促進されています。

当レポートでは、世界の血友病遺伝子治療市場を調査し、市場の概要、血友病タイプ・地域別の市場規模の推移と予測、市場の成長要因および阻害要因、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 調査目的と前提条件

  • 調査目的
  • 前提条件
  • 略語

第2章 市場の視野

  • レポートの説明
    • 市場の定義と範囲
  • エグゼクティブサマリー
    • 市場スニペット:血友病タイプ別
    • 市場スニペット:地域別
  • コヒーレントオポチュニティマップ(COM)

第3章 市場力学・規制・動向分析

  • 市場力学
    • 成長要因
    • 阻害要因
    • 市場機会
  • 影響分析
  • パイプライン分析
  • 合併・買収・提携
  • 規制シナリオ
  • PEST分析
  • 疫学データ

第4章 世界の血友病遺伝子治療市場:血友病タイプ別

  • イントロダクション
  • 血友病A
  • 血友病B

第5章 世界の血友病遺伝子治療市場:地域別

  • イントロダクション
  • 北米
  • ラテンアメリカ
  • 欧州
  • アジア太平洋地域
  • 中東
  • アフリカ

第6章 競争環境

  • 市場シェア分析
  • 会社のプロファイル
    • BioMarin Pharmaceuticals, Inc.
    • Spark Therapeutics
    • Pfizer, Inc.
    • UniQure NV
    • Ultragenyx Pharmaceutical
    • Shire PLC
    • Sangamo Therapeutics, Inc
    • Freeline Therapeutics
  • アナリストの意見

第7章 セクション

  • 参考文献
  • 調査方法
  • Coherent Market Insightsについて
目次

Hemophilia is a genetic disorder in which patient's blood do not clot normally due to lack of blood-clotting proteins known as coagulating factors. Conventional treatment options include timely replacement of the specific clotting factor. Major pharma and biotech companies are conducting research and development to develop gene therapy for hemophilia due to various shortcomings with conventional therapy. Increasing number of hemophilic patients that require treatment and strong product pipeline are expected to drive growth of the hemophilia gene therapy market.

Market Dynamics

Major factors that are driving growth of the hemophilia gene therapy market include increasing prevalence of hemophilia, issue of high cost, access to current hemophilia treatment, which includes coagulation factor VIII and IX, and increasing number of companies engaged in research and development of gene therapy products. According to the Centers for Disease Control and Prevention, hemophilia A is a rare, X-linked bleeding disorder that affects around 1 in 5,000 to 10,000 live-born males. Hemophilia B is less common than hemophilia A, with an incidence of around 1 in 25,000 births. According to 2016 global survey by the World Federation of Hemophilia, the total number of individuals with hemophilia worldwide was 184,723, including 16,949 within the U.S.

Key features of the study:

  • This report provides in-depth analysis of the global hemophilia gene therapy market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2018 - 2026), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, pipeline analysis, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global hemophilia gene therapy market based on the following parameters - company overview, financial performance, market presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include BioMarin Pharmaceuticals, Inc., Spark Therapeutics, Pfizer, Inc., UniQure NV, Ultragenyx Pharmaceutical, Shire PLC, Sangamo Therapeutics, Inc., and Freeline Therapeutics
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, product up-gradation, market expansion, and marketing tactics
  • The global hemophilia gene therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the hemophilia gene therapy market

Detailed Segmentation

  • Global Hemophilia Gene Therapy Market, By Type:
  • Hemophilia A
  • Hemophilia B
  • Global Hemophilia Gene Therapy Market, By Region:
  • North America
    • By Type
  • Hemophilia A
  • Hemophilia B
    • By Country:
  • U.S.
  • Canada
  • Latin America
    • By Type
  • Hemophilia A
  • Hemophilia B
    • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Type
  • Hemophilia A
  • Hemophilia B
    • By Country:
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Type
  • Hemophilia A
  • Hemophilia B
    • By Country:
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Type
  • Hemophilia A
  • Hemophilia B
    • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Type
  • Hemophilia A
  • Hemophilia B
    • By Country:
  • South Africa
  • Central Africa
  • North Africa
  • Company Profiles
  • BioMarin Pharmaceuticals, Inc. *
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Market Strategies
  • Spark Therapeutics
  • Pfizer, Inc.
  • UniQure NV
  • Ultragenyx Pharmaceutical
  • Shire PLC
  • Sangamo Therapeutics
  • Freeline Therapeutics

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Hemophilia Type
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Pipeline Analysis
  • Primary Research Respondents View About Market
  • Mergers, Acquisitions, and Collaborations
  • Regulatory Scenario
  • PEST Analysis
  • Epidemiological Data

4. Global Hemophilia Gene Therapy Market, By Product Type, 2018 - 2026, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2017 and 2025 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Hemophilia A
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
  • Hemophilia B
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)

5. Global Hemophilia Gene Therapy Market, By Region, 2018 - 2026, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2017 and 2026 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017 - 2026
  • North America
    • Market Size and Forecast, By Hemophilia Type, 2016 - 2026, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Hemophilia Type, 2016 - 2026, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Hemophilia Type, 2016 - 2026, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Hemophilia Type, 2016 - 2026, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Hemophilia Type, 2016 - 2026, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Hemophilia Type, 2016 - 2026, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

6. Competitive Landscape

  • Market Share Analysis
  • Company Profiles
    • BioMarin Pharmaceuticals, Inc.*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Spark Therapeutics
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • UniQure NV
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Ultragenyx Pharmaceutical
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Shire PLC
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Sangamo Therapeutics, Inc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Freeline Therapeutics
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
  • Analyst Views

7. Section

  • References
  • Research Methodology
  • About us and Sales Contact
Back to Top